STAT+: At BIO 2026, industry wrestled with Washington politics, and making AI work better
Biotech executives reveal concerns over Chinese biotech, the profitability of AI, and the durability of Trump's drug price moves.
Record details
Published: 25 June 2026
Source: STAT News (health AI, headlines)
Category: News
Topics: Healthcare · Biotech
Retrieved: 14 July 2026
Related evidence
These records share source-supplied organisations, an exact publisher byline, automatic topics or regions. The reason is shown on every link; related does not mean supporting, agreeing with or verifying this record.
This renewable energy source is actually terrible for the planet
Vox Future Perfect · 14 July 2026
Chinese biotech giant WuXi AppTec sees first-half earnings surge amid US scrutiny
SCMP Tech (HK/CN) · 3 August 2026
FTC Secures Major Settlement with Caremark, Resolving Antitrust Case Against Second Drug Middleman
US FTC Press Releases · 14 July 2026
Navigating the Global Regulatory Landscape for Exosome-Based Therapeutics: Challenges, Strategies, and Future Directions
OpenAlex · 30 July 2025
Prediction and diagnosis of renal cell carcinoma using nuclear magnetic resonance-based serum metabolomics and self-organizing maps
OpenAlex · 24 July 2016
STAT+: AI scientist company Edison Scientific tapped by team behind Metsera to create new biotechs
STAT News (health AI, headlines) · 29 June 2026
How to cite this record
ethics.ai (25 June 2026), “STAT+: At BIO 2026, industry wrestled with Washington politics, and making AI work better,” evidence record 2753, https://ethics.ai/record/2753 (originally published by STAT News (health AI, headlines)).
Use and limitations
This page is a stable index and citation surface for a source record. ethics.ai did not author the underlying report and has not independently verified every claim. Automatic topics may be imperfect. For consequential use, quote and cite the original publisher.